Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.

Keyphrases

• Gemcitabine 100%
• Unresectable Locally Advanced 100%
• Metastatic Bladder Cancer 100%
• Locally Advanced Bladder Cancer 100%
• Advanced or Metastatic 100%
• Gemcitabine Plus Cisplatin 72%
• Randomized Trial 54%
• Carboplatin 45%
• Cisplatin 36%
• Methotrexate 36%
• Vinblastine 36%
• Overall Survival 36%
• Paclitaxel 27%
• Doxorubicin 27%
• No Significant Difference 27%
• Response Rate 18%
• Randomized Controlled Trial 9%
• Treatment Choice 9%
• Safety Profile 9%
• Clinical Management 9%
• Metastatic Disease 9%
• Randomized Clinical Trial 9%
• Systemic Chemotherapy 9%
• Alopecia 9%
• Data Extraction 9%
• Severe Acute 9%
• Disease Stage 9%
• MEDLINE 9%
• Embase 9%
• Mucositis 9%
• New Agents 9%
• Progression-free Survival 9%
• Inclusion Criteria 9%
• Maintenance Scheduling 9%
• Cisplatin-based Chemotherapy 9%
• Search Strategy 9%
• 1-year Survival 9%
• Web of Science 9%
• Disease-specific Survival 9%
• CINAHL 9%
• Risk-benefit Ratio 9%
• Neutropenic Sepsis 9%
• Cytotoxic Agents 9%
• Acute Toxicity 9%
• Cochrane Database of Systematic Reviews 9%
• Large Trials 9%
• Weekly Schedule 9%
• Bladder Transitional Cell Carcinoma 9%
• Unfit for Cisplatin 9%
• Weekly Regimen 9%
• 6-cycles 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 100%
• Gemcitabine 100%
• Cisplatin 68%
• Carboplatin 26%
• Methotrexate 21%
• Overall Survival 21%
• Vinblastine 21%
• Doxorubicin 15%
• Paclitaxel 15%
• Chemotherapy 10%
• Diseases 10%
• Randomized Controlled Trial 5%
• Randomized Clinical Trial 5%
• Acute Toxicity 5%
• Alopecia 5%
• Progression Free Survival 5%
• Survival Rate 5%
• Mucosa Inflammation 5%
• Disease Specific Survival 5%
• Sepsis 5%
• Transitional Cell Carcinoma 5%
• Cytotoxic Agent 5%